Previous Close | 0.9600 |
Open | 0.9312 |
Bid | 0.8402 x 2200 |
Ask | 1.0000 x 900 |
Day's Range | 0.8722 - 0.9700 |
52 Week Range | 0.5500 - 2.1000 |
Volume | |
Avg. Volume | 187,755 |
Market Cap | 68.63M |
Beta (5Y Monthly) | 1.39 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.5200 |
Earnings Date | Mar 19, 2024 - Mar 23, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 3.67 |
Subscribe to Yahoo Finance Plus to view Fair Value for VNRX
VolitionRx Limited (NYSE American: VNRX) ("Volition"), a multi-national epigenetics company, is taking part in a webinar hosted by Edison Group, to update stakeholders on recent developments and ongoing studies for its Nu.Q® NETs test.
The International Monetary Fund believes that most of the impact from tighter money policies has already affected the U.S. economy, with the rest expected this year. Despite worries about a recession, the U.S. has shown resilience and strong growth since interest rates started going up in March 2022. This suggests a positive outlook for the U.S. economy in the coming months. With our economy, looking to perform well this year you need to invest in these biotech stocks that will provide high retu
VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has issued a Business Review of 2023, outlining its key highlights from the past year.